Skip to main contentSkip to navigationSkip to search
Curasight

Curasight A/S presents at Nordnet Live - Spotlight Small Cap investor conference 15 April 2021

April 9, 2021

Regulatory

Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans, at the Nordnet Live platform 15 April 2021, 16:20 (CET). The presentation will be webcasted live.

For more information and registration please click here

The event will be moderated by Brian Buus (Head of Business Management, Nordnet)

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Downloads

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.